| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $620K | -4.9% | — |
| SG&A Expense | $1.2M | -39.1% | +308.2% |
| Operating Income | -$1.8M | +30.8% | -514.7% |
| Net Income | -$1.8M | +33.1% | -435.7% |
| EPS (Basic) | -$0.14 | +46.2% | -250.0% |
| EPS (Diluted) | -$0.14 | +46.2% | -250.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $7.0M | -20.0% | — |
| Current Assets | $9.1M | -12.2% | — |
| Total Assets | $9.3M | -12.3% | — |
| Current Liabilities | $1.1M | +34.7% | — |
| Total Liabilities | $1.1M | +34.7% | — |
| Stockholders' Equity | $8.2M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.1M | — | — |
| Capital Expenditures | $36K | — | — |
| Investing Cash Flow | -$36K | — | — |
| Financing Cash Flow | $12.1M | — | — |
| Free Cash Flow | -$5.1M | — | — |
| -16.2% |
| +879.8% |